Sangamo Therapeutics: On the Brink of Breakthrough or Bankruptcy
Overview
Sangamo Therapeutics is a clinical-stage genomic medicine company pioneering treatments for severe neurological diseases using its proprietary ZFP platform. Its most advanced asset—a gene therapy for Fabry disease—has produced compelling data and secured a potentially accelerated FDA regulatory pathway. Despite this scientific promise, Sangamo is in a severe financial crisis, with the survival of the company hinging on securing a commercialization partner for its Fabry program before its cash runs out in late 2025. The promise of its neurology pipeline is significant but too nascent to impact near-term viability. The investment narrative is therefore defined by high potential sharply counterbalanced by urgent financial peril.